Stifel analyst Tom Stephan upgraded STAAR Surgical (STAA) from Hold to Buy, raising the price target to $31, based on anticipated 'meaningful upside' to Street estimates for 2026 and 2027. The upgrade is driven by reaccelerating growth in China's refractive market and the company's potential for higher revenue growth than current consensus.
Stifel analyst Tom Stephan upgraded STAAR Surgical (STAA) to Buy from Hold, increasing the price target from $28 to $31. This upgrade is a significant positive catalyst for STAA, as it signals increased confidence in the company's future performance, particularly in the lucrative China market. The analyst projects an 11% CAGR for revenue between 2026 and 2028, significantly higher than the consensus 8%, driven by a rebound in China's refractive market and a favorable mix shift towards higher-ASP products like EVO+. This suggests potential for sustained long-term growth, but traders should monitor actual sales figures from China and the adoption rate of EVO+ to confirm the thesis. The share repurchase authorization also indicates management's confidence and commitment to shareholder value.